Inflammaging
Chronic, low-grade, systemic inflammation that accompanies aging even without an active infection — a term coined in 2000 by Claudio Franceschi, today considered one of the fundamental mechanisms linking aging to age-related disease.
Number of studies
3
Safety
High
Time to effects
This is a process that builds up gradually over decades, not a phenomenon with a single point of onset — increased inflammaging is measurable in population studies as early as middle age, with a marked acceleration after age 60.
Who it's for
Table of contents
TL;DR
Chronic, low-grade, systemic inflammation that accompanies aging even without an active infection — a term coined in 2000 by Claudio Franceschi, today considered one of the fundamental mechanisms linking aging to age-related disease.
- →The concept helps explain the mechanistic link between aging and chronic diseases of old age
- →Explains why inflammatory markers (e.g., hsCRP) are sometimes moderately elevated in apparently healthy older people without active infection
- →Points to specific, modifiable indirect targets (gut barrier, body weight, physical activity) rather than treating aging as a fully inevitable process
| Who coined the term | Claudio Franceschi and colleagues, 2000, based on research into centenarians |
|---|---|
| Type of phenomenon | Chronic, sterile (infection-free), low-grade systemic inflammation |
| Key markers | IL-6, TNF-α, IL-1β, CRP/hsCRP |
| Main sources | SASP from senescent cells, metabolic endotoxemia, mitochondrial DAMPs |
| Linked diseases | Atherosclerosis, insulin resistance, sarcopenia, neurodegeneration |
| Connection | Tightly coupled with immunosenescence — 'two sides of the same coin' |
| Research level | Moderate — the concept is well established, interventions with proven efficacy are limited |
Understand
Overview
Inflammaging (from inflammation + aging) is a term coined in 2000 by Italian immunologist Claudio Franceschi and colleagues, based on years of research into centenarians as a model of longevity. It describes chronic, systemic, low-grade inflammation that increases with age even in the absence of overt infection or disease — a sterile inflammation, qualitatively distinct from the acute immune response to a pathogen or injury. Franceschi described it as "a global reduction in the capacity to cope with a variety of stressors and a concomitant progressive increase in the pro-inflammatory status."
Inflammaging is characterized by chronically elevated levels of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), acute-phase proteins (including CRP — see the separate entry on CRP and hsCRP), and the accumulation of senescent cells, which secrete the so-called SASP (senescence-associated secretory phenotype) — a cocktail of pro-inflammatory factors that keeps the tissue environment in a state of chronic activation. This phenomenon is linked in observational studies to a wide range of age-related diseases: atherosclerosis and cardiovascular disease, insulin resistance and type 2 diabetes, sarcopenia, and also neurodegeneration, including Alzheimer's disease.
Who can this knowledge realistically help? People interested in the mechanisms linking aging to chronic disease — inflammaging is today treated as one of the "hallmarks" of biological aging, alongside things like mitochondrial dysfunction or telomere shortening. But this isn't a disease entity with a ready-made "treatment for inflammaging" — available strategies (an anti-inflammatory diet, physical activity, maintaining a healthy body weight, attention to the gut microbiome) work indirectly, by reducing the factors that drive this process, rather than "curing" it directly.
Mechanism of action
The sources of inflammaging are multifactorial. A key role is played by the accumulation of senescent cells, which escape apoptosis yet remain metabolically active and secrete SASP — a mix of cytokines, chemokines, and matrix metalloproteinases that degrade the extracellular matrix, acting paracrinely on neighboring tissue and systemically through circulation. A second significant source is the age-related increase in gut barrier permeability (so-called 'leaky gut'), which allows bacterial fragments, especially lipopolysaccharide (LPS), to enter circulation and trigger chronic, low-grade activation of the immune system — a phenomenon known as metabolic endotoxemia. A third mechanism is the release of mitochondrial DNA and other intracellular danger signals (DAMPs) from damaged cells, activating intracellular sensors such as the cGAS-STING pathway, which signals the presence of 'foreign' DNA and drives a pro-inflammatory response.
The effect of these processes is chronic activation of the NF-κB transcriptional pathway in numerous cell types, producing a constant, low-level pro-inflammatory 'hum' throughout the body. Unlike acute inflammation, which is self-limiting and purposeful (fighting a specific pathogen, healing an injury), inflammaging is chronic and diffuse, burdening tissues without a clear defensive goal — it's precisely this sterile persistence that links it to rising risk of cardiovascular, metabolic, and neurodegenerative disease, and mechanistically couples it tightly with immunosenescence (see the separate entry) in a vicious cycle of mutual reinforcement.
Accumulation of senescent cells and SASP
Senescent cells escape apoptosis and secrete a cocktail of pro-inflammatory cytokines that act locally and systemically.
Increased gut permeability
Age-related weakening of the gut barrier allows bacterial fragments (LPS) to enter circulation, triggering metabolic endotoxemia.
Release of danger signals (DAMPs)
Damaged cells release mitochondrial DNA and other intracellular signals, activating pathways such as cGAS-STING.
Chronic activation of NF-κB
The combined effect of these signals is constant, low-grade activation of the pro-inflammatory transcriptional pathway across many body tissues.
Evidence: moderate — based on 3 studies in this database.
Benefits
Common myths
MythInflammaging is the same thing as acute inflammation after an injury or infection.
FactIt's a qualitatively different process — chronic, sterile (infection-free), low-grade systemic inflammation, unlike the acute, self-limiting, and purposeful response to a specific pathogen or injury.
MythA normal CRP result within the standard lab reference range rules out inflammaging.
FactInflammaging is sometimes described at hsCRP values still within the laboratory reference range, but elevated relative to that person's younger age — a single normal result doesn't rule out a chronically elevated pro-inflammatory baseline.
Personalized for you
Struggling with sleep?
Answer a few questions about your sleep, stress, diet, and lifestyle. VitMode will show you which areas might need the most attention and which supplements could be worth considering.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
There's no single, universal test for inflammaging — in scientific studies it's usually assessed through a panel of markers (IL-6, TNF-α, hsCRP, and others), not a single parameter. A single hsCRP result provides only a partial picture.
Diets rich in vegetables, fruit, omega-3 fatty acids, and fiber (e.g., the Mediterranean diet) are linked in observational and some interventional studies to lower inflammatory markers in older adults, though the effect size tends to be moderate and the mechanism is partly mediated by effects on the gut microbiome.
Acute inflammation after an infection is intense, purposeful, and self-limiting — it resolves once the threat is cleared. Inflammaging is chronic, low-grade, and sterile (without an active pathogen), persisting for years as a backdrop to the aging process.
No — the severity of inflammaging varies substantially between people of the same chronological age, partly depending on lifestyle, body weight, gut microbiome status, and genetics. Centenarians studied by Franceschi's team often showed a milder course of this process than the average population.
What to combine with
Good combinations
Immunosenescence — Both phenomena drive each other and are described as two aspects of the same process of immune-system aging
CRP and hs-CRP — hsCRP is one of the most commonly used laboratory markers for indirectly assessing the severity of inflammaging
Gut Microbiome — Disruption of the microbiome and gut permeability is one of the main modifiable factors driving inflammaging
Safety
Side effects & contraindications
Possible side effects
Contraindications
No significant contraindications at typical doses.
Is it worth taking?
Who it's for
- People interested in the mechanisms linking chronic inflammation to diseases of old age
- People tracking their inflammatory markers (e.g., hsCRP) who want to understand the context for interpreting them at older ages
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
The term 'inflammaging' was coined in 2000 by Claudio Franceschi based on years of research into Italian centenarians.
Senescent cells secrete SASP — a cocktail of pro-inflammatory cytokines — even without dividing or undergoing apoptosis.
Inflammaging and immunosenescence are sometimes described as 'two sides of the same coin,' mutually reinforcing each other.
Studies
A global reduction in the capacity to cope with a variety of stressors and a concomitant progressive increase in the pro-inflammatory status are among the main features of the aging process.
Franceschi C, et al., Annals of the New York Academy of Sciences, 2000
Inflamm-aging. An evolutionary perspective on immunosenescence
Research hypothesisFranceschi C, Bonafè M, Valensin S, et al. · Annals of the New York Academy of Sciences · 2000
The paper that coined the term 'inflamm-aging' based on years of research into centenarians — proposes an evolutionary theoretical framework linking chronic inflammation to immune-system aging.
View studyChronic inflammation (inflammaging) and its potential contribution to age-associated diseases
Moderate evidenceFranceschi C, Campisi J. · The Journals of Gerontology: Series A · 2014
A review systematizing evidence linking chronic, low-grade inflammation to diseases of old age, including cardiovascular, metabolic, and neurodegenerative conditions.
View studyImmunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?
Moderate evidenceFulop T, Larbi A, Dupuis G, et al. · Frontiers in Immunology · 2018
A review describing the tight, bidirectional link between inflammaging and immunosenescence as two aspects of the same immune-aging process.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
121 publications on this site
Medical review
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
174 publications on this site
Related entries
4.2Immunosenescence
The progressive, multi-directional remodeling of the immune system with age — not a simple 'weakening,' but a complex change that both lowers the ability to fight new threats and raises the baseline level of inflammation.
4.5CRP and hs-CRP
A protein produced by the liver in response to inflammation — in its high-sensitivity form (hs-CRP) it has become one of the most widely studied additional markers of cardiovascular risk.
4.6Gut Microbiome
Trillions of bacteria, viruses, and fungi colonizing the gut aren't a passive "passenger" in the body — they're an active ecosystem influencing digestion, immunity, and even mood, with an increasingly well-documented, though still not fully mapped, role in whole-body health.
4.05-AVAB
5-aminovaleric acid betaine (5-AVAB) is a small molecule produced by the gut bacterium Bifidobacterium pseudocatenulatum, whose levels decline with age — in mice, giving it reduced age-related inflammation and improved cognitive and motor function.
4.3Autophagy
An intracellular 'housekeeping' process that clears out damaged proteins and organelles, whose discovery earned a Nobel Prize — one of the key mechanisms studied in the context of slowing aging.
4.2TFEB
The transcription factor TFEB acts as a master on-off switch for autophagy and the production of new lysosomes in the cell — one of the best-characterized molecular nodes linking these two processes, studied as a potential target for interventions in aging.
4.2NAD+ Recycling
The level of NAD+ in the body isn't just about how much of the coenzyme a cell makes from scratch — it's mainly about how efficiently it reclaims NAD+ from the byproducts of its own breakdown, a process called the salvage pathway, whose efficiency declines with age regardless of how much precursor is supplied through diet or supplements.
4.1NMN (Nicotinamide Mononucleotide)
An NAD+ precursor intensively studied in the context of cellular aging — human data are still early, despite huge market popularity.
Related articles
PoradnikiMediterranean Diet and Longevity: How Much Does It Really Lower Death Risk?
"The Mediterranean diet extends life" is one of those statements repeated so often that almost no one asks for the actual numbers. By how much, exactly? For whom? And is this an effect visible after a few weeks, or only after decades of consistent adherence? In this article we break the topic down, drawing on the largest available meta-analysis (over 4 million participants) and a separate study focused specifically on older adults — two sources that together give a far fuller picture than the popular, oversimplified headlines.
August 23, 2026
Badania naukoweWhat we now know about NMN and longevity — a review of human studies
NMN, a precursor of NAD+, has for years been one of the most hotly debated supplements in the biohacking community. We look at what the latest clinical trials in humans show, as distinct from earlier studies in mice.
August 11, 2026
Badania naukoweLongevity Vitamins: Which Supplements Actually Have Real Scientific Evidence Behind Them
Every supplement shelf promises a longer life in every capsule, but the hard data from large clinical trials tells a far more measured story. We go through which vitamins genuinely extend healthy lifespan in people with a real deficiency, and which — despite their popularity — have no supporting evidence at all, or worse, evidence of no benefit.
August 20, 2026
PoradnikiNMN vs NAD+ vs Resveratrol — What Actually Extends Life?
Three of the biggest names in longevity, one shared hypothesis, and a very different level of evidence in humans for each. An honest comparison of mechanism, clinical trial quality, and monthly cost — with no marketing rounding up.
August 20, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.